Humoral response to BNT162b2-COVID-19 or CoronaVac vaccine against COVID-19 in people with multiple sclerosis patients treated with high efficacy therapies

被引：0
|
作者：
Galleguillos, L. [1 ]
Alonso, R. [2 ]
Kagi, M. [3 ]
Hernandez, M. [1 ]
Diaz, V. [1 ]
Pallauta, K. [4 ]
Jerez, M. E. [4 ]
机构：
[1] Clin Alemana, Neurol & Psiquiatria, Santiago, Chile
[2] Hosp Ramos Mejia, Neurol, Buenos Aires, DF, Argentina
[3] Clin Davila, Neurol & Neurocirugia, Santiago, Chile
[4] Univ Los Andes, Neurol, Santiago, Chile
来源：
MULTIPLE SCLEROSIS JOURNAL | 2021年 / 27卷 / 2_SUPPL期
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
P974
引用
收藏
页码：792 / 792
页数：1
相关论文
共 50 条
  • [1] Humoral response to BNT162b2-COVID-19 or CoronaVac vaccine in NMOSD and MOGAD Patients
    Galleguillos, L.
    Alonso, R.
    Villacura, J.
    Diaz, V.
    Hernandez, M.
    MULTIPLE SCLEROSIS JOURNAL, 2021, 27 (2_SUPPL) : 781 - 782
  • [2] Effect of highly effective treatments in patients with multiple sclerosis on humoral responses to BNT162B2-COVID-19 or CORONAVAC vaccines
    Galleguillos, Lorna
    Alonso, Ricardo
    Kagi, Marianne
    MULTIPLE SCLEROSIS JOURNAL, 2022, 28 (02) : NP10 - NP10
  • [3] Effect of treatments on humoral responses to BNT162B2-COVID-19 or coronavac vaccines in nmosd and mogad patients
    Galleguillos, Lorna
    Alonso, Ricardo
    Villacura, Jorge
    Diaz, Violeta
    Hernandez, Marianella
    MULTIPLE SCLEROSIS JOURNAL, 2022, 28 (02) : NP15 - NP16
  • [4] Humoral immune response to COVID-19 mRNA (BNT162b2-Pfizer) vaccine in patients with multiple sclerosis
    Karussis, D.
    Karni, A.
    Milo, R.
    Staun-Ram, E.
    Miller, A.
    MULTIPLE SCLEROSIS JOURNAL, 2021, 27 (2_SUPPL) : 766 - 767
  • [5] Six-month humoral response to BNT162b2 mRNA COVID-19 vaccine in people with multiple sclerosis treated with natalizumab
    Altieri, Manuela
    Capuano, Rocco
    Conte, Miriana
    Donnarumma, Giovanna
    Grimaldi, Elena
    Coppola, Nicola
    Galdiero, Massimiliano
    D'Ambrosio, Alessandro
    Tedeschi, Gioacchino
    Gallo, Antonio
    NEUROLOGICAL SCIENCES, 2022, 43 (05) : 2947 - 2949
  • [6] Six-month humoral response to BNT162b2 mRNA COVID-19 vaccine in people with multiple sclerosis treated with natalizumab
    Manuela Altieri
    Rocco Capuano
    Miriana Conte
    Giovanna Donnarumma
    Elena Grimaldi
    Nicola Coppola
    Massimiliano Galdiero
    Alessandro d’Ambrosio
    Gioacchino Tedeschi
    Antonio Gallo
    Neurological Sciences, 2022, 43 : 2947 - 2949
  • [7] Efficacy of BNT162b2 and CoronaVac in patients diagnosed with COVID-19
    Dogan, Mustafa
    Yilmaz, Berna
    ACTA PHARMACEUTICA, 2023, 73 (02) : 257 - 268
  • [8] BNT162b2 mRNA Vaccine Against Covid 19, Humoral Response, Safety and Efficacy in Scleroderma Patients
    Braun-Moscovici, Yolanda
    Kaplan, Marielle
    Braun, Maya
    Markovits, Doron
    Giryes, Sami
    Toledano, Kohava
    Tavor, Yonit
    Dolnikov, Katya
    Daood, Rula
    Balbir-Gurman, Alexandra
    ARTHRITIS & RHEUMATOLOGY, 2022, 74 : 4319 - 4320
  • [9] Humoral response and safety of the third booster dose of BNT162b2 mRNA COVID-19 vaccine in patients with multiple sclerosis treated with ocrelizumab or fingolimod
    Rocco Capuano
    Manuela Altieri
    Miriana Conte
    Alvino Bisecco
    Alessandro d’Ambrosio
    Giovanna Donnarumma
    Elena Grimaldi
    Nicola Coppola
    Nicola Medici
    Massimiliano Galdiero
    Gioacchino Tedeschi
    Antonio Gallo
    Journal of Neurology, 2022, 269 : 6185 - 6192
  • [10] Humoral response and safety of the third booster dose of BNT162b2 mRNA COVID-19 vaccine in patients with multiple sclerosis treated with ocrelizumab or fingolimod
    Capuano, Rocco
    Altieri, Manuela
    Conte, Miriana
    Bisecco, Alvino
    D'Ambrosio, Alessandro
    Donnarumma, Giovanna
    Grimaldi, Elena
    Coppola, Nicola
    Medici, Nicola
    Galdiero, Massimiliano
    Tedeschi, Gioacchino
    Gallo, Antonio
    JOURNAL OF NEUROLOGY, 2022, 269 (12) : 6185 - 6192
12345